Q4 2019 Share Price Performance

Feb 28 17:02 2020 Print This Article

Q4 2019 Share Price Performance

Healthcare Stocks Surge 

In this blog post, the Bloom Burton equity research team summarizes the performance of the Canadian healthcare sector during 4Q-2019, and provides commentary on select stock movements and overall market trends. 

Inclusion Criteria 

Our analysis includes all Canadian publicly-listed healthcare companies, defined as companies that are Canadian headquartered and/or listed on Canadian exchanges, with an enterprise value (EV) of C$10 MM or greater. Our definition of healthcare includes companies operating in the following areas: therapeutic R&D; commercial therapeutics; healthcare services; healthcare IT; medical devices; medical supplies; diagnostics; and consumer health. We do not include medical cannabis producers (unless they are developing cannabis-based products under the traditional drug development regulatory process) or companies that operate long term care facilities. Based on these criteria we identified 98 companies.

Read More

About Article Author

Cross Border Biotech Blog

Bloom Burton & Co. is Canada's leading biotechnology and healthcare-specialized investment banking firm, which exists to accelerate returns in healthcare. Bloom Burton has an experienced team of medical, scientific, pharmaceutical, legal and capital markets professionals who perform a deeper level of diligence, which combined with a creative and entrepreneurial approach, leads to the right monetization events for companies and investors. Bloom Burton provides capital raising, M&A advisory, equity research, management consulting, direct investments through equity and debt funds, and company creation services.

Related Items

Market Update: Investors Optimistic as Global Economies Reopen

The quickest bear market in the history of the US S&P 500 turned into the best 50-day bull market rally in history in May. By market close on June 3, 2020, the S&P 500 Index was up 37.7% from its March 23, 2020 low. This bullish investor sentiment has been based on the continued decline in new coro ...

“E” vs “SG” in ethical investing: how sustainable is mollification-by-cherrypicking

In the great game of whack-a-mole that is capital raising in Canada’s oil patch, it must be frustrating, for those whose full-time job when there isn’t a global pandemic is whacking the moles of ESG criteria on which they feel their companies may be vulnerable to criticism and hence subject to ...

A deep retrofit of homes and buildings is the megaproject Canada needs

Ramping down carbon emissions from homes and buildings can help us rebuild Canada’s economy after the pandemic. ...

Rebuilding Canada’s economy includes energy resiliency in remote communities (blog)

This is the moment to create a roadmap for a society that is more resilient to these macro shocks – whether they are brought about by a pandemic or climate change. Canada’s response must support a more resilient, healthier economy that is competitive and shows economic strength in a decarbonize ...

Customer Success: Formulary Management

In response to customer requests, we’ve built some new tools for formulary management. You can preview these tools at: Recent Generic Drug Launches Upcoming 180-Day Patent Challenge Exclusivity Expirations Anticipate… The post Customer Success: Formulary Management appeared first on DrugPatentW ...

Ottawa postpones short-sighted drug-pricing regulations

Author: Bacchus Barua Planned changes would likely result in fewer new and innovative drugs available to Canadians. Read more about Ottawa postpones short-sighted drug-pricing regulations Tags:  pmprb pharmaceutical drugs pharmaceutical innovation prescription drug prices ...

Zymeworks ticks all the boxes for a biopharma investment, Paradigm says

Zymeworks (Zymeworks Stock Quote, Chart, News NYSE:ZYME) has what investors should be looking for in a biopharmaceutical company, according to Paradigm Capital analyst Corey Hammill, namely, a strong balance sheet and a healthy-looking pipeline. The analyst reviewed Zymeworks latest quarterly resul ...

Q4 2019 Share Price Performance

Q4 2019 Share Price Performance Healthcare Stocks Surge  In this blog post, the Bloom Burton equity research team summarizes the performance of the Canadian healthcare sector during 4Q-2019, and provides commentary on select stock movements and overall market trends.  Inclusion Criteria  Our ana ...

Filipino Healthcare Workers During COVID-19 and the Importance of Race-Based Analysis

Filipino Workers on the Frontlines During COVID19 Globally and in Canada Warlito Valdez. Amor Padilla Gatinao. Daisy Dorinilla. Debbie Accad. Leilani Medel. Christine Mandegarian.  These are just a few of the names of Filipino nurses, personal support workers, and caregivers in Canada, the United ...

Answers to FAQs about the recent market disruption

Global Market Strategist Brian Levitt provides perspective on the impact of the coronavirus and oil price wars.   1. Wasn’t the market due for a correction anyway? Market drawdowns typically don’t just happen for no apparent reason. They are the result of economic and/or policy uncertainty. Th ...

MedX Health has tons of upside, says Beacon Securities

Beacon Securities analyst Doug Cooper thinks the market has so far ignored a series of recent game-changing announcements by medical technology company MedX Health (MedX Health Stock Quote, Chart, News TSXV:MDX). That scenario, said Cooper in a June 16 update to clients, makes for a prime investmen ...

Profound Medical is insulated from COVID-19, says Raymond James

Looking for bright spots within the ongoing market deluge? Raymond James analyst Rahul Sarugaser says Profound Medical (Profound Medical Stock Quote, Chart, News TSX:PRN) should be top of mind, as the company appears to be well-insulated with respect to the COVID-19 pandemic. In an update to client ...